Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.72 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.72 |
| ▸ | RARB | P10826 | 9/20 | 0.72 |
| ▸ | RARG | P13631 | 9/20 | 0.72 |
| ▸ | RARA | P10276 | 6/20 | 0.72 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | RXRA | P19793 | 13/20 | 0.52 |
| ▸ | RXRB | P28702 | 12/20 | 0.52 |
| ▸ | RXRG | P48443 | 10/20 | 0.52 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8875459 | 0.86 | CYP3A4 (0.67) | CYP3A4CYP26A1RARBRARGRARA | |
| SCHEMBL24410699 | 0.85 | RARB (0.71) | CYP3A4CYP26A1RARBRARGRARA | |
| SCHEMBL9337024 | 0.84 | CYP3A4 (0.84) | CYP3A4CYP26A1RARBRARGRARA | |
| SCHEMBL6665934 | 0.84 | RARB (0.76) | CYP3A4CYP26A1RARBRARGRARA | |
| Tazarotenic Acid SCHEMBL29433140 | 0.84 | CYP3A4 (1.00) | CYP3A4CYP26A1RARBRARGRARA | |
| Tazarotenic Acid SCHEMBL29466098 | 0.84 | CYP3A4 (1.00) | CYP3A4CYP26A1RARBRARGRARA | |
| SCHEMBL1320433 | 0.84 | CYP3A4 (0.65) | CYP3A4CYP26A1RARBRARGRARA | |
| Tazarotenic Acid SCHEMBL678713 | 0.84 | CYP3A4 (1.00) | CYP3A4CYP26A1RARBRARGRARA | |
| SCHEMBL7636138 | 0.84 | CYP3A4 (0.62) | CYP3A4CYP26A1RARBRARGRARA | |
| SCHEMBL9270697 | 0.84 | CYP3A4 (0.77) | CYP3A4CYP26A1RARBRARGRARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020068665-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2020-04-02 | — | — | WO | claimed |
| US-5556844-A | SYNERGISTIC, SKIN DISORDERS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1996-09-17 | — | — | US | claimed |
| EP-0465343-B1 | Pharmaceutical or cosmetical composition comprising a retinoid and a sterol in association | CIRD GALDERMA (FR) | 1994-06-15 | — | — | EP | claimed |
| EP-0284261-B1 | Acetylenes disubstituted with a heteroaromatic group and a tetralin group having retinoid like activity | ALLERGAN INC (US) | 1994-01-05 | — | — | EP | claimed |
| US-5149705-A | Treatment of psoriasis | ALLERGAN, INC. (US) | 1992-09-22 | — | — | US | claimed |
| US-20220144783-A1 | SYNTHETIC RETINOIDS FOR USE IN RAR ACTIVATION | UNIVERSITY OF DURHAM (GB) | 2022-05-12 | — | — | US | disclosed |
| US-20210338558-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2021-11-04 | — | — | US | disclosed |
| WO-2020068665-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2020-04-02 | — | — | WO | disclosed |
| US-20080255244-A1 | Administering a Calmodulin-dependent protein kinase (M kinase II) gamma inhibitor; acute myelogenous leukemia, chronic myelogenous leukemia, gastrointestinal stromal tumor, small cell lung cancer, non-small cell lung cancer, ovarian cancer | FRED HUTCHINSON CANCER RESEARCH CENTER | 2008-10-16 | — | — | US | disclosed |
| US-5587367-A | SYNERGISTIC EFFECT IN TREATING SKIN DISORDERS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1996-12-24 | — | — | US | disclosed |
| US-5556844-A | SYNERGISTIC, SKIN DISORDERS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1996-09-17 | — | — | US | disclosed |
| US-5466690-A | Treating psoriasis | ALLERGAN, INC. (US) | 1995-11-14 | — | — | US | disclosed |
| US-5354776-A | Treating psoriasis | ALLERGAN, INC. (US) | 1994-10-11 | — | — | US | disclosed |
| EP-0284261-B1 | Acetylenes disubstituted with a heteroaromatic group and a tetralin group having retinoid like activity | ALLERGAN INC (US) | 1994-01-05 | — | — | EP | disclosed |
| US-5246962-A | Psoriasis, skin disorders | ALLERGAN, INC. (US) | 1993-09-21 | — | — | US | disclosed |
| US-5149705-A | Treatment of psoriasis | ALLERGAN, INC. (US) | 1992-09-22 | — | — | US | disclosed |
| EP-0284261-A1 | Acetylenes disubstituted with a heteroaromatic group and a tetralin group having retinoid like activity | ALLERGAN, INC (US) | 1988-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338558-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | COL14A1, COL2A1, COL1A1 | CYP3A4 4195/4885CYP26A1 1489/4885RARB 987/4885 |
| US-20220144783-A1 | SYNTHETIC RETINOIDS FOR USE IN RAR ACTIVATION | RARA, RXRA, RARB | CYP3A4 870/4885CYP26A1 53/4885RARB 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.